Amgen And Novartis Present New Data Demonstrating Long-Term Efficacy, Safety And Tolerability Of Aimovig ™ (erenumab-aooe) In Patients With Chronic And Episodic Migraine

Results From a One-Year Study of Efficacy and Safety of Aimovig in Chronic Migraine and Data From a Three-Year Analysis Assessing Safety and Tolerability of Aimovig in Episodic Migraine Will be Presented at the American Headache Society Annual Meeting Aimovig Showed Robust Efficacy in Patients With Chronic Migraine, With Reductions in Monthly Migraine Days Sustained Throughout the Study Established Safety Profile of Aimovig Reinforced With Chronic and Episodic Migraine Data THOUSAND OAKS, Calif., June 28, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the results of two open-label extension (OLE) studies of Aimovig™ (erenumab-ao...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news